Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
All images were downloaded from the PCDS website: Accessed on 30 Aug 2019
By the Numbers (Clinical Trial Averages): Tirzepatide Wins for: Greater Average Weight Loss: 22.5% vs 14.9% More Patients Reaching 20% Loss: 63% vs not reported Higher Percentage Reaching 15% Loss: 78% vs 50.5% Continued Weight Loss: Patients continued losing weight throughout 72 weeks Semaglutide Still Highly Effective: 86% of patients lost at least 5% of body weight 69% of patients lost at least 10% of body weight Longer market history with real-world data Proven cardiovascular benefits in studies Factors Beyond Weight Loss Numbers: Side Effect Tolerance: If you experience severe nausea with one medication, the one you can actually take consistently is the more effective choice for you
The Future is Personalized Treatment will be in conjunction with and at the discretion of the provider.* Your Journey is Personal
When fatty acids struggle to move efficiently into the mitochondria, your body leans more heavily on glycogen
Tirzepatide carries a warning about acute pancreatitis in its prescribing information, and alcohol is one of the two leading causes of pancreatitis globally (alongside gallstones)
US$ 20.77
US$ 22.69
US$ 25.00
